Service provision and use of anticoagulants in atrial fibrillation.
Several large trials have shown that the risk of stroke in patients with non-valvar atrial fibrillation is reduced by treatment with warfarin. Implementing this research evidence requires not only an understanding of the trials' results and of the changes that they imply for clinicians' treatment decisions but also an appreciation of the organisation, quantity, and quality of services required to support these changes. Understanding of these implications is crucial for developing services that allow changes in practice to produce reductions in stroke incidence while minimising the risks of treatment. This article considers the developments in service provision that will probably be required to support the changes in clinical practice suggested by the trials' results. These services will be provided largely by doctors, and their development has implications for doctors in both primary and secondary care.
Sudlow
C M
CM
Department of Medicine, Medical School, University of Newcastle upon Tyne.
Rodgers
H
H
Kenny
R A
RA
Thomson
R G
RG
D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000191:economics; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D006301:Health Services Needs and Demand; D006801:Humans; D018579:Patient Selection; D010818:Practice Patterns, Physicians'; D011787:Quality of Health Care; D006113:United Kingdom; D014859:Warfarin / Q000191:economics / Q000627:therapeutic use*
D014859:Warfarin